Trials / Recruiting
RecruitingNCT06228053
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- Syntrix Biosystems, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SX-682 | Specified dose twice daily |
| DRUG | Enzalutamide | Specified dose once daily |
Timeline
- Start date
- 2024-11-18
- Primary completion
- 2026-06-30
- Completion
- 2028-06-30
- First posted
- 2024-01-29
- Last updated
- 2025-12-22
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06228053. Inclusion in this directory is not an endorsement.